Cargando…

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

PURPOSE: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors. Pemetrexed is polyglutamated by the folylpolyglutamate synthase (FPGS) and blocks folate metabolism and DNA synthesis by inhibiting TS, dihydrofolate reductase (D...

Descripción completa

Detalles Bibliográficos
Autores principales: Nannizzi, Sara, Veal, Gareth J., Giovannetti, Elisa, Mey, Valentina, Ricciardi, Simona, Ottley, Christopher J., Del Tacca, Mario, Danesi, Romano
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886085/
https://www.ncbi.nlm.nih.gov/pubmed/20020129
http://dx.doi.org/10.1007/s00280-009-1195-2
_version_ 1782182439331823616
author Nannizzi, Sara
Veal, Gareth J.
Giovannetti, Elisa
Mey, Valentina
Ricciardi, Simona
Ottley, Christopher J.
Del Tacca, Mario
Danesi, Romano
author_facet Nannizzi, Sara
Veal, Gareth J.
Giovannetti, Elisa
Mey, Valentina
Ricciardi, Simona
Ottley, Christopher J.
Del Tacca, Mario
Danesi, Romano
author_sort Nannizzi, Sara
collection PubMed
description PURPOSE: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors. Pemetrexed is polyglutamated by the folylpolyglutamate synthase (FPGS) and blocks folate metabolism and DNA synthesis by inhibiting TS, dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study evaluates the pharmacological interaction between oxaliplatin and pemetrexed in colorectal cancer cells. METHODS: Human HT29, WiDr, SW620 and LS174T cells were treated with oxaliplatin and pemetrexed. Drug interaction was studied using the combination index method, while cell cycle was investigated with flow cytometry. The effects of drugs on Akt phosphorylation and apoptosis were studied with ELISA and fluorescence microscopy, respectively. RT-PCR analysis was performed to assess whether drugs modulated the expression of pemetrexed targets and of genes involved in DNA repair (ERCC1 and ERCC2). Finally, platinum–DNA adduct levels were detected by ultra-sensitive multi-collector inductively coupled plasma mass spectrometry (ICP-MS). RESULTS: A dose-dependent inhibition of cell growth was observed after drug exposure, while a synergistic interaction was detected preferentially with sequential combinations. Oxaliplatin enhanced cellular population in the S-phase. Drug combinations increased apoptotic indices with respect to single agents, and both drugs inhibited Akt phosphorylation. RT-PCR analysis showed a correlation between the FPGS/(TS × DHFR × GARFT) ratio and pemetrexed sensitivity, as well as a downregulation of ERCC1, ERCC2, TS, DHFR and GARFT after drug exposure. In addition, pretreatment with pemetrexed resulted in an increase of oxaliplatin–DNA adducts. CONCLUSION: These data demonstrate that oxaliplatin and pemetrexed synergistically interact against colon cancer cells, through modulation of cell cycle, inhibition of Akt phosphorylation, induction of apoptosis and modulation of gene expression.
format Text
id pubmed-2886085
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-28860852010-07-21 Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines Nannizzi, Sara Veal, Gareth J. Giovannetti, Elisa Mey, Valentina Ricciardi, Simona Ottley, Christopher J. Del Tacca, Mario Danesi, Romano Cancer Chemother Pharmacol Original Article PURPOSE: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors. Pemetrexed is polyglutamated by the folylpolyglutamate synthase (FPGS) and blocks folate metabolism and DNA synthesis by inhibiting TS, dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study evaluates the pharmacological interaction between oxaliplatin and pemetrexed in colorectal cancer cells. METHODS: Human HT29, WiDr, SW620 and LS174T cells were treated with oxaliplatin and pemetrexed. Drug interaction was studied using the combination index method, while cell cycle was investigated with flow cytometry. The effects of drugs on Akt phosphorylation and apoptosis were studied with ELISA and fluorescence microscopy, respectively. RT-PCR analysis was performed to assess whether drugs modulated the expression of pemetrexed targets and of genes involved in DNA repair (ERCC1 and ERCC2). Finally, platinum–DNA adduct levels were detected by ultra-sensitive multi-collector inductively coupled plasma mass spectrometry (ICP-MS). RESULTS: A dose-dependent inhibition of cell growth was observed after drug exposure, while a synergistic interaction was detected preferentially with sequential combinations. Oxaliplatin enhanced cellular population in the S-phase. Drug combinations increased apoptotic indices with respect to single agents, and both drugs inhibited Akt phosphorylation. RT-PCR analysis showed a correlation between the FPGS/(TS × DHFR × GARFT) ratio and pemetrexed sensitivity, as well as a downregulation of ERCC1, ERCC2, TS, DHFR and GARFT after drug exposure. In addition, pretreatment with pemetrexed resulted in an increase of oxaliplatin–DNA adducts. CONCLUSION: These data demonstrate that oxaliplatin and pemetrexed synergistically interact against colon cancer cells, through modulation of cell cycle, inhibition of Akt phosphorylation, induction of apoptosis and modulation of gene expression. Springer-Verlag 2009-12-18 2010 /pmc/articles/PMC2886085/ /pubmed/20020129 http://dx.doi.org/10.1007/s00280-009-1195-2 Text en © The Author(s) 2009 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Nannizzi, Sara
Veal, Gareth J.
Giovannetti, Elisa
Mey, Valentina
Ricciardi, Simona
Ottley, Christopher J.
Del Tacca, Mario
Danesi, Romano
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title_full Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title_fullStr Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title_full_unstemmed Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title_short Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
title_sort cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886085/
https://www.ncbi.nlm.nih.gov/pubmed/20020129
http://dx.doi.org/10.1007/s00280-009-1195-2
work_keys_str_mv AT nannizzisara cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT vealgarethj cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT giovannettielisa cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT meyvalentina cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT ricciardisimona cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT ottleychristopherj cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT deltaccamario cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines
AT danesiromano cellularandmolecularmechanismsforthesynergisticcytotoxicityelicitedbyoxaliplatinandpemetrexedincoloncancercelllines